BR100 Increased By (0.01%)
BR30 Decreased By (-1.15%)
KSE100 Increased By (0.09%)
KSE30 Decreased By (-0.05%)
AGHA 6.02 Decreased By ▼ -0.03 (-0.5%)
BECO 3.81 Decreased By ▼ -0.02 (-0.52%)
BML 56.44 Decreased By ▼ -1.89 (-3.24%)
BOP 28.10 Decreased By ▼ -0.25 (-0.88%)
CNERGY 12.28 Decreased By ▼ -1.36 (-9.97%)
CSIL 5.29 Increased By ▲ 0.08 (1.54%)
FCCL 53.81 Increased By ▲ 1.53 (2.93%)
FFL 12.80 Decreased By ▼ -0.10 (-0.78%)
FNEL 1.12 Decreased By ▼ -0.01 (-0.88%)
KEL 5.64 Decreased By ▼ -0.15 (-2.59%)
KOSM 5.38 Decreased By ▼ -0.13 (-2.36%)
LOTCHEM 23.55 Decreased By ▼ -0.34 (-1.42%)
MLCF 91.96 Increased By ▲ 1.45 (1.6%)
NBP 162.24 Increased By ▲ 2.52 (1.58%)
NCPL 48.91 Decreased By ▼ -0.69 (-1.39%)
NPL 50.51 Decreased By ▼ -1.29 (-2.49%)
OGDC 301.68 Decreased By ▼ -5.10 (-1.66%)
PACE 9.13 Decreased By ▼ -0.02 (-0.22%)
PAEL 31.81 Decreased By ▼ -0.52 (-1.61%)
PIBTL 12.78 Decreased By ▼ -0.15 (-1.16%)
PPL 212.06 Decreased By ▼ -1.87 (-0.87%)
PRL 87.26 Decreased By ▼ -9.70 (-10%)
PTC 43.96 Decreased By ▼ -1.23 (-2.72%)
SSGC 22.86 Increased By ▲ 0.33 (1.46%)
TBL 8.91 Decreased By ▼ -0.11 (-1.22%)
TELE 6.44 Decreased By ▼ -0.28 (-4.17%)
TPL 24.09 Decreased By ▼ -1.82 (-7.02%)
TPLP 12.16 Decreased By ▼ -0.44 (-3.49%)
TREET 23.50 Increased By ▲ 0.04 (0.17%)
TRG 51.87 Decreased By ▼ -0.09 (-0.17%)
World

EU has not yet ordered more AstraZeneca vaccines, says internal market commissioner

  • Breton said an increase in prices for second generation vaccines could be justified by the extra research required and potential changes to industrial equipment.
Published Updated
By

PARIS: The European Union has not yet made any new orders for AstraZeneca vaccines beyond June when their contract ends, European Internal Market Commissioner Thierry Breton said on Sunday.

Breton also said he expected that the costs of the EU's recent order for more doses of Pfizer-BioNTech vaccines would be higher than the earlier versions.

The Commission last month launched legal action against AstraZeneca for not respecting its contract for the supply of COVID-19 vaccines and for not having a "reliable" plan to ensure timely deliveries.

"We did not renew the order after June. We'll see what happens," said Breton, adding that it was "a very good vaccine".

Concerns has risen on potential side-effects of the Anglo-Swedish COVID-19 vaccine.

Europe's medicines regulator said on Friday it is reviewing reports of a rare nerve-degenerating disorder in people who received the shots, a move that comes after it found the vaccine may have caused very rare blood clotting cases.

Breton said an increase in prices for second generation vaccines could be justified by the extra research required and potential changes to industrial equipment.

The European Union signed a new contract with Pfizer-Biontech to receive 1.8 billion doses of COVID-19 vaccines for 2021-2023, to cover booster shots, donations and reselling of doses, the European Commission said on Friday.

"There may be a little extra cost but I will let the competent authorities unveil it in due course," he told France Inter radio.

Comments

Comments are closed for this article.